Credit Suisse’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-93,147
| Closed | -$16M | – | 4765 |
|
|
2021
Q3 | $16M | Buy |
93,147
+27,812
| +43% | +$3.64M | 0.01% | 1208 |
|
|
2021
Q2 | $8.2M | Buy |
65,335
+1,941
| +3% | +$245K | ﹤0.01% | 1704 |
|
|
2021
Q1 | $8.6M | Sell |
63,394
-6,252
| -9% | -$808K | ﹤0.01% | 1681 |
|
|
2020
Q4 | $8.91M | Sell |
69,646
-2,526
| -3% | -$296K | ﹤0.01% | 1657 |
|
|
2020
Q3 | $8.12M | Sell |
72,172
-9,293
| -11% | -$925K | 0.01% | 1493 |
|
|
2020
Q2 | $7.76M | Buy |
81,465
+5,832
| +8% | +$562K | 0.01% | 1435 |
|
|
2020
Q1 | $6.8M | Buy |
75,633
+20,869
| +38% | +$1.62M | 0.01% | 1373 |
|
|
2019
Q4 | $2.9M | Sell |
54,764
-155,976
| -74% | -$7.11M | ﹤0.01% | 2306 |
|
|
2019
Q3 | $8.33M | Buy |
210,740
+155,723
| +283% | +$6.76M | 0.01% | 1420 |
|
|
2019
Q2 | $2.26M | Buy |
55,017
+7,500
| +16% | +$311K | ﹤0.01% | 2374 |
|
|
2019
Q1 | $2.21M | Buy |
47,517
+1,990
| +4% | +$87.4K | ﹤0.01% | 2298 |
|
|
2018
Q4 | $1.98M | Buy |
45,527
+10,229
| +29% | +$511K | ﹤0.01% | 2248 |
|
|
2018
Q3 | $2.02M | Sell |
35,298
-5,206
| -13% | -$256K | ﹤0.01% | 2341 |
|
|
2018
Q2 | $1.96M | Sell |
40,504
-10,964
| -21% | -$399K | ﹤0.01% | 2471 |
|
|
2018
Q1 | $2.01M | Buy |
51,468
+13,624
| +36% | +$579K | ﹤0.01% | 2419 |
|
|
2017
Q4 | $1.61M | Sell |
37,844
-52,128
| -58% | -$1.96M | ﹤0.01% | 2623 |
|
|
2017
Q3 | $3.36M | Sell |
89,972
-43,902
| -33% | -$1.52M | ﹤0.01% | 2110 |
|
|
2017
Q2 | $4.07M | Sell |
133,874
-16,257
| -11% | -$471K | ﹤0.01% | 1766 |
|
|
2017
Q1 | $3.97M | Sell |
150,131
-1,032
| -0.7% | -$27.2K | ﹤0.01% | 1822 |
|
|
2016
Q4 | $3.86M | Sell |
151,163
-55,456
| -27% | -$1.76M | ﹤0.01% | 1854 |
|
|
2016
Q3 | $7.48M | Sell |
206,619
-183,034
| -47% | -$6.06M | 0.01% | 1370 |
|
|
2016
Q2 | $13.2M | Buy |
389,653
+248,775
| +177% | +$8.09M | 0.01% | 995 |
|
|
2016
Q1 | $3.72M | Buy |
140,878
+48,518
| +53% | +$1.41M | ﹤0.01% | 1746 |
|
|
2015
Q4 | $4.5M | Buy |
92,360
+1,938
| +2% | +$69.7K | 0.01% | 1666 |
|
|
2015
Q3 | $2.25M | Sell |
90,422
-27,373
| -23% | -$823K | ﹤0.01% | 2172 |
|
|
2015
Q2 | $3.73M | Buy |
117,795
+9,271
| +9% | +$299K | ﹤0.01% | 1999 |
|
|
2015
Q1 | $4.13M | Buy |
108,524
+8,281
| +8% | +$329K | ﹤0.01% | 1816 |
|
|
2014
Q4 | $3.91M | Buy |
100,243
+74,029
| +282% | +$2.58M | ﹤0.01% | 1970 |
|
|
2014
Q3 | $793K | Sell |
26,214
-13,642
| -34% | -$384K | ﹤0.01% | 3262 |
|
|
2014
Q2 | $1.35M | Buy |
39,856
+29,172
| +273% | +$975K | ﹤0.01% | 3040 |
|
|
2014
Q1 | $368K | Buy |
10,684
+5,455
| +104% | +$246K | ﹤0.01% | 3947 |
|
|
2013
Q4 | $207K | Buy |
+5,229
| New | +$126K | ﹤0.01% | 4309 |
|
Credit Suisse's XLRN Position: Q4 2021 in Review
Credit Suisse sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 93,147 shares — an estimated $16M sold.
Credit Suisse first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $16M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Credit Suisse reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Credit Suisse sold 93,147 Acceleron Pharma shares in Q4 2021, an estimated $16M.
- Credit Suisse first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Credit Suisse's Acceleron Pharma position peaked at $16M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.